Shares of Plandai Biotechnology (PLPL) traded light on Tuesday even after the penny stock became a recommended “BUY” in the recent KonLin Letter. PLPL stock traded triple the 20-day average volume, 51,504, but failed to capture the short-term message of Konrad Kuhn who anticipates Plandai’s income for 2012-2013 to reach $27 million, tripling to $90 million within the next ...
8
AUG
AUG
0
Share
In 